Cholesterol synthesis inhibitors in cholesterol gallstone disease.

Cholesterol synthesis inhibitors in cholesterol gallstone disease. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Cholesterol synthesis inhibitors in cholesterol gallstone disease. Abstract Text:

J W Smit,K J VanErpecum,G P VanBerge-Henegouwen,

Cholesterol synthesis inhibitors (HMG-CoA Reductase Inhibitors) are reported to decrease cholesterol saturation index of duodenal bile in hypercholesterolaemic subjects. The dissolution of gallstones in animals on treatment with these drugs created expectations of a therapeutical role for these drugs in cholesterol gallstone disease. However, in prospective studies with these drugs in humans, no effect on number and size of cholesterol gallstones was observed. This is likely the result of the fact that not just biliary secretion of cholesterol is decreased during treatment with these drugs in cholesterol gallstone disease, but phospholipids and bile salts as well. As a consequence, nucleation time of cholesterol crystals in gallbladder bile is not influenced by these drugs. Another important determinant in cholesterol gallstone disease, e.g. gallbladder motility, is not influenced by HMG-CoA reductase inhibitors. Although these drugs and their metabolites are secreted into the bile, they do not influence biliary lithogenicity. In conclusion, there seems to be no therapeutic role for HMG-CoA reductase inhibitors in the treatment of cholesterol gallstone disease, although no negative effects on determinants of cholesterol gallstone formation during treatment with these drugs are observed either.

Cholesterol synthesis inhibitors in cholesterol gallstone disease. Publishing Authors By Initials

JW Smit,KJ VanErpecum,GP VanBerge-Henegouwen,

For similar diagnosis: prognosis research abstracts see: diagnosis: prognosis research

PUBMED ID PMID:

MEDLINE DATE:

Cholesterol synthesis inhibitors in cholesterol gallstone disease. Journal Published:

PUBLICATION TYPE: Review

Journal: Scandinavian journal of gastroenterology. Suppleme

VOLUME: 218

Page Numbers: 56-60

Journal Abbreviation: Scand. J. Gastroenterol. Suppl

ISSN: 0085-5928

DAY: 13

MONTH: 02

YEAR: 1996

Cholesterol synthesis inhibitors in cholesterol gallstone disease. Information

Number of References: 66

LANGUAGE: eng

NlmUniqueID: 437034

Cholesterol synthesis inhibitors in cholesterol gallstone disease. Keywords Mesh Terms:

KEYWORDS: Prognosis

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Cholesterol synthesis inhibitors in cholesterol gallstone disease. Information

Substance Name: methylglutaconyl-CoA hydratase

Registry Number: EC 4.2.1.18

Grant and Affiliation Information for Cholesterol synthesis inhibitors in cholesterol gallstone disease.

AFFILIATION: Dept. of Gastroenterology, University Hospital, Utrecht, The Netherlands.

Country: NORWAY

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Scand J Gastroenterol Suppl

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Cholesterol synthesis inhibitors in cholesterol gallstone disease Related Publications

• Acute idiopathic pancreatitis: does it really exist or is it a myth?
• An update on the pathogenesis and treatment of cholesterol gallstones.
• Cholesterol synthesis inhibitors in cholesterol gallstone disease.